Department of Biotechnology, College of Biomedical & Health Science, Konkuk University, Chungju 27478, Korea.
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul 03722, Korea.
Int J Mol Sci. 2021 Jul 24;22(15):7914. doi: 10.3390/ijms22157914.
The outbreak of the coronavirus disease 2019 (COVID-19) began at the end of 2019. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and patients with COVID-19 may exhibit poor clinical outcomes. Some patients with severe COVID-19 experience cytokine release syndrome (CRS) or a cytokine storm-elevated levels of hyperactivated immune cells-and circulating pro-inflammatory cytokines, including interleukin (IL)-1β and IL-18. This severe inflammatory response can lead to organ damage/failure and even death. The inflammasome is an intracellular immune complex that is responsible for the secretion of IL-1β and IL-18 in various human diseases. Recently, there has been a growing number of studies revealing a link between the inflammasome and COVID-19. Therefore, this article summarizes the current literature regarding the inflammasome complex and COVID-19.
2019 年底爆发了 2019 冠状病毒病（COVID-19）。COVID-19 是由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）感染引起的，COVID-19 患者可能出现不良临床结局。一些严重 COVID-19 患者会经历细胞因子释放综合征（CRS）或细胞因子风暴-过度激活的免疫细胞和循环促炎细胞因子水平升高，包括白细胞介素（IL）-1β和 IL-18。这种严重的炎症反应可导致器官损伤/衰竭，甚至死亡。炎性小体是一种细胞内免疫复合物，负责在各种人类疾病中分泌 IL-1β和 IL-18。最近，越来越多的研究揭示了炎性小体与 COVID-19 之间的联系。因此，本文总结了目前关于炎性小体复合物与 COVID-19 的文献。
